Key Takeaways
- • 424 Capital has exited Reverba, a Seattle-based health engagement firm, through a strategic sale, according to PEI Private Equity.
- • Reverba helps pharmaceutical and biotech companies engage with patients and healthcare professionals across the therapy lifecycle.
- • The transaction is a healthcare-services exit for the sponsor; the primary source does not disclose the buyer, deal value, or holding period.
Summary
Reverba provides engagement services to pharmaceutical and biotechnology companies, helping them connect with patients and healthcare professionals across the full therapy lifecycle. The company's position in that niche places it within the commercial and patient-engagement services market that life sciences companies increasingly outsource.
The primary source does not identify the acquirer, the purchase price, or when 424 Capital originally invested. Readers seeking those terms should consult the original PEI report or subsequent filings.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.